Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: A modelling approach
2011

Costs and Frequency of Adverse Drug Events in Germany

Sample size: 2000000 publication Evidence: moderate

Author Information

Author(s): Renee G Stark, Jürgen John, Reiner Leidl

Primary Institution: Helmholtz Zentrum München - German Research Center for Environmental Health

Hypothesis

What are the frequency and costs of adverse drug events (ADEs) in outpatient treatment in Germany?

Conclusion

The study found that the costs of adverse drug events in the ambulatory setting in Germany are significant, totaling 816 million Euros.

Supporting Evidence

  • The study estimated that about 2 million adults in Germany experienced an ADE in 2007.
  • Health care costs related to ADEs totaled 816 million Euros, with significant portions from hospitalizations and long-term care.
  • The average cost per ADE case was estimated at 381 Euros.

Takeaway

This study shows that many people in Germany have problems with their medications that can lead to extra costs for healthcare.

Methodology

A cost-of-illness model was adapted to estimate the frequency and costs of ADEs in Germany, using sensitivity analyses based on literature.

Potential Biases

The model may not accurately reflect the true incidence of ADEs due to data scarcity and reliance on U.S. treatment structures.

Limitations

The study relies on limited data from two German hospitals, which may not represent the entire country.

Participant Demographics

The study focused on adults over 20 years of age taking medications in Germany.

Digital Object Identifier (DOI)

10.1186/1472-6963-11-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication